Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Sertralina

Zoloft, Tatig e altri

Bibliografia - Quali fonti bibliografiche per Sertralina?

1. Abman S.H., Pediatr. Pulmonol. Suppl., 1999, 18, 201.

2. Alwan S. et al., NEJM, 2007, 356, 2684.

3. Bandelow B. et al., J. Clin. Psychiatry, 2004, 65 (3), 405.

4. Boer R.A. et al., BMC Emergency Medicine, 2005, 5, 5.

5. Carson H.J. et al., Am. J. Forensic Med. Pathol., 2000, 21, 273.

6. Casper R.C. et al., J. Pediatr., 2003, 142, 402.

7. Chambers C.D. et al., NEJM, 2006, 354, 579.

8. Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.

9. De Abajo F.J. et al., BMJ, 1999, 319, 1106.

10. Doogan D.P., Caillard V., Br. J. Psychiatry, 1992, 160, 217.

11. Drug Ther. Bull., 1991, 4 (13), 51.

12. Expertise Collective Inserm, Les édition Inserm: Paris; 2003.

13. Fisekonc' S., Loga-Zec S., Bosn. J. Basic Med. Sci., 2005, 5 (2), 78.

14. Glassman A.H. et al., JAMA, 2002, 288, 701.

15. Gulseren L. et al., Arch. Med. Res., 2005, 36 (2), 159.

16. Hoechns J.D. et al., Ann. Pharmacother., 2001, 35, 862.

17. Kmijima K. et al., Int. Clin. Psychopharmacol., 2005, 20 5), 265.

18. Kirby D. et al., Internet J. Ger. Psychiatry, 2002, 17, 231.

19. Jureidini J.N. et al., BMJ, 2004, 328, 879.

20. Laine K. et al., Arch. Gen. Psychiatry, 2003, 60, 720.

21. Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.

22. Louik C. et al., NEJM, 2007, 356, 2675.

23. Malm H. et al., Obstet. Gynecol., 2005, 106, 1289.

24. Markowitz J.S., DeVane C.L., J. Clin. Psychopharmacol., 2000, 20, 109.

25. Mason P.J. et al., Medicine, 2000, 79, 201.

26. Mills J.L., NEJM, 2006, 354, 636.

27. Morag I. et al., J. Toxicol. Clin. 2004, 42, 97.

28. Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.

29. Murdock D., McTavish D., Drugs, 1992, 44 (4), 604.

30. Nace D.A., Towers A., J. Am. Ger. Soc., 1999, 47, S32.

31. NICE – National Institute for Health and Clinical Excellence, 2007, disponibile online www.nice.org.uk/nicemedia/pdf/CG23fullguideline.pdf

32. Nielsen J.A. et al., Am. J. Clin. Nutr., 1992, 55, 185S.

33. Nulman I. et al., Am. J. Psychiatry, 2002, 159, 1889.

34. Oberlander T.F. et al., Pediatr. Res., 2002, 51, 443.

35. Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.

36. Patron C. Ferrier I.N., BMJ, 2005, 334, 529.

37. Rey J. et al., Rheumatology, 2003, 42, 601.

38. Sansone R.A., Sansone L.A., Int. J. Psychiatry Med., 2003, 33 (1), 103.

39. Serebruany V.L., Am. J. Med., 2006, 119, 113.

40. Stone Z.N. et al., Am. J. Psychiatry, 1997, 154, 1255.

41. Trenque T. et al., Pharmacoepidemiol. Drug Safety, 2002, 11, 281.

42. van Walraven C. et al., BMJ, 2001, 323, 655.

43. Yonkers K.A. et al., JAMA, 1997, 278, 983.

44. Wagner K.D. et al., JAMA, 2003, 290, 1033.

45. Walkup J.T. et al., NEJM, 2008, 359, 2753.

46. Warrington S.J., Int. Clin. Psychopharmacol., 1991, 6 (Suppl. 2), 11.

47. Weissman A.M. et al., Am. J. Psychiatry, 2004, 161, 1066.

48. Zeskind P.S., Stephens L.E., Pediatrics, 2004, 113, 368.

49. Zeskind P.S. et al., Pediatr. Res., 2005, 57, 1624.